(EXAS) EXACT Sciences - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US30063P1057
Stock: Cancer Tests, Genetic Testing, Tumor Profiling, Risk Assessment
Total Rating 54
Risk 31
Buy Signal 0.59
| Risk 5d forecast | |
|---|---|
| Volatility | 2.53% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.88 |
| Alpha | 113.94 |
| Character TTM | |
|---|---|
| Beta | -0.059 |
| Beta Downside | -1.026 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.30% |
| CAGR/Max DD | 0.32 |
EPS (Earnings per Share)
Revenue
Description: EXAS EXACT Sciences March 06, 2026
Exact Sciences Corporation (EXAS) develops and commercializes cancer screening and diagnostic tests. The companys product portfolio includes Cologuard for colorectal cancer screening and Oncotype DX tests for breast and colon cancer recurrence. This business model relies on intellectual property and clinical validation for market adoption.
EXAS also offers genetic testing and tumor profiling services. The companys pipeline focuses on various stages of cancer care, from risk assessment to recurrence monitoring. The biotechnology sector, in which Exact Sciences operates, is characterized by extensive research and development investments.
Further research on ValueRay can provide more in-depth analysis of Exact Sciences financial performance and market position.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -207.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 4.83 > 1.0 |
| NWC/Revenue: 24.28% < 20% (prev 30.42%; Δ -6.14% < -1%) |
| CFO/TA 0.08 > 3% & CFO 491.4m > Net Income -207.9m |
| Net Debt (1.57b) to EBITDA (42.6m): 36.77 < 3 |
| Current Ratio: 2.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (189.7m) vs 12m ago 2.39% < -2% |
| Gross Margin: 69.69% > 18% (prev 0.67%; Δ 6902 % > 0.5%) |
| Asset Turnover: 55.09% > 50% (prev 46.54%; Δ 8.55% > 0%) |
| Interest Coverage Ratio: -4.88 > 6 (EBITDA TTM 42.6m / Interest Expense TTM 36.6m) |
Altman Z'' -3.37
| A: 0.13 (Total Current Assets 1.43b - Total Current Liabilities 641.2m) / Total Assets 5.86b |
| B: -0.80 (Retained Earnings -4.71b / Total Assets 5.86b) |
| C: -0.03 (EBIT TTM -179.0m / Avg Total Assets 5.89b) |
| D: -1.36 (Book Value of Equity -4.70b / Total Liabilities 3.46b) |
| Altman-Z'' Score: -3.37 = D |
Beneish M -3.02
| DSRI: 1.02 (Receivables 298.7m/249.0m, Revenue 3.25b/2.76b) |
| GMI: 0.97 (GM 69.69% / 67.25%) |
| AQI: 1.03 (AQ_t 0.61 / AQ_t-1 0.60) |
| SGI: 1.18 (Revenue 3.25b / 2.76b) |
| TATA: -0.12 (NI -207.9m - CFO 491.4m) / TA 5.86b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of EXAS shares?
As of March 07, 2026, the stock is trading at USD 103.50 with a total of 1,549,793 shares traded.
Over the past week, the price has changed by +0.07%, over one month by +0.64%, over three months by +2.24% and over the past year by +116.92%.
Over the past week, the price has changed by +0.07%, over one month by +0.64%, over three months by +2.24% and over the past year by +116.92%.
Is EXAS a buy, sell or hold?
EXACT Sciences has received a consensus analysts rating of 4.54.
Therefore, it is recommended to buy EXAS.
- StrongBuy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXAS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 105.8 | 2.2% |
| Analysts Target Price | 105.8 | 2.2% |
EXAS Fundamental Data Overview March 06, 2026
P/E Forward = 188.6792
P/S = 6.0741
P/B = 8.2284
P/EG = -1.07
Revenue TTM = 3.25b USD
EBIT TTM = -179.0m USD
EBITDA TTM = 42.6m USD
Long Term Debt = 2.33b USD (from longTermDebt, last quarter)
Short Term Debt = 67.2m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.57b USD (from netDebt column, last quarter)
Enterprise Value = 21.28b USD (19.72b + Debt 2.52b - CCE 964.7m)
Interest Coverage Ratio = -4.88 (Ebit TTM -179.0m / Interest Expense TTM 36.6m)
EV/FCF = 59.65x (Enterprise Value 21.28b / FCF TTM 356.8m)
FCF Yield = 1.68% (FCF TTM 356.8m / Enterprise Value 21.28b)
FCF Margin = 10.99% (FCF TTM 356.8m / Revenue TTM 3.25b)
Net Margin = -6.40% (Net Income TTM -207.9m / Revenue TTM 3.25b)
Gross Margin = 69.69% ((Revenue TTM 3.25b - Cost of Revenue TTM 984.2m) / Revenue TTM)
Gross Margin QoQ = 70.11% (prev 68.64%)
Tobins Q-Ratio = 3.63 (Enterprise Value 21.28b / Total Assets 5.86b)
Interest Expense / Debt = 0.33% (Interest Expense 8.20m / Debt 2.52b)
Taxrate = 21.0% (US default 21%)
NOPAT = -141.4m (EBIT -179.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.23 (Total Current Assets 1.43b / Total Current Liabilities 641.2m)
Debt / Equity = 1.05 (Debt 2.52b / totalStockholderEquity, last quarter 2.40b)
Debt / EBITDA = 36.77 (Net Debt 1.57b / EBITDA 42.6m)
Debt / FCF = 4.39 (Net Debt 1.57b / FCF TTM 356.8m)
Total Stockholder Equity = 2.44b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.53% (Net Income -207.9m / Total Assets 5.86b)
RoE = -8.51% (Net Income TTM -207.9m / Total Stockholder Equity 2.44b)
RoCE = -3.75% (EBIT -179.0m / Capital Employed (Equity 2.44b + L.T.Debt 2.33b))
RoIC = -2.97% (negative operating profit) (NOPAT -141.4m / Invested Capital 4.77b)
WACC = 5.53% (E(19.72b)/V(22.25b) * Re(6.20%) + D(2.52b)/V(22.25b) * Rd(0.33%) * (1-Tc(0.21)))
Discount Rate = 6.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 2.32%
[DCF] Terminal Value 80.82% ; FCFF base≈243.9m ; Y1≈160.1m ; Y5≈73.0m
[DCF] Fair Price = 3.99 (EV 2.33b - Net Debt 1.57b = Equity 760.8m / Shares 190.9m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 83.75 | EPS CAGR: 144.8% | SUE: -2.75 | # QB: 0
Revenue Correlation: 98.07 | Revenue CAGR: 17.06% | SUE: 1.10 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.30 | Chg7d=+0.000 | Chg30d=-0.002 | Revisions Net=+3 | Analysts=3
EPS current Year (2026-12-31): EPS=1.14 | Chg7d=+0.000 | Chg30d=+0.017 | Revisions Net=+3 | Growth EPS=+1521.4% | Growth Revenue=+12.8%
EPS next Year (2027-12-31): EPS=1.88 | Chg7d=+0.000 | Chg30d=-0.275 | Revisions Net=-2 | Growth EPS=+65.6% | Growth Revenue=+12.4%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)
P/S = 6.0741
P/B = 8.2284
P/EG = -1.07
Revenue TTM = 3.25b USD
EBIT TTM = -179.0m USD
EBITDA TTM = 42.6m USD
Long Term Debt = 2.33b USD (from longTermDebt, last quarter)
Short Term Debt = 67.2m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.57b USD (from netDebt column, last quarter)
Enterprise Value = 21.28b USD (19.72b + Debt 2.52b - CCE 964.7m)
Interest Coverage Ratio = -4.88 (Ebit TTM -179.0m / Interest Expense TTM 36.6m)
EV/FCF = 59.65x (Enterprise Value 21.28b / FCF TTM 356.8m)
FCF Yield = 1.68% (FCF TTM 356.8m / Enterprise Value 21.28b)
FCF Margin = 10.99% (FCF TTM 356.8m / Revenue TTM 3.25b)
Net Margin = -6.40% (Net Income TTM -207.9m / Revenue TTM 3.25b)
Gross Margin = 69.69% ((Revenue TTM 3.25b - Cost of Revenue TTM 984.2m) / Revenue TTM)
Gross Margin QoQ = 70.11% (prev 68.64%)
Tobins Q-Ratio = 3.63 (Enterprise Value 21.28b / Total Assets 5.86b)
Interest Expense / Debt = 0.33% (Interest Expense 8.20m / Debt 2.52b)
Taxrate = 21.0% (US default 21%)
NOPAT = -141.4m (EBIT -179.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.23 (Total Current Assets 1.43b / Total Current Liabilities 641.2m)
Debt / Equity = 1.05 (Debt 2.52b / totalStockholderEquity, last quarter 2.40b)
Debt / EBITDA = 36.77 (Net Debt 1.57b / EBITDA 42.6m)
Debt / FCF = 4.39 (Net Debt 1.57b / FCF TTM 356.8m)
Total Stockholder Equity = 2.44b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.53% (Net Income -207.9m / Total Assets 5.86b)
RoE = -8.51% (Net Income TTM -207.9m / Total Stockholder Equity 2.44b)
RoCE = -3.75% (EBIT -179.0m / Capital Employed (Equity 2.44b + L.T.Debt 2.33b))
RoIC = -2.97% (negative operating profit) (NOPAT -141.4m / Invested Capital 4.77b)
WACC = 5.53% (E(19.72b)/V(22.25b) * Re(6.20%) + D(2.52b)/V(22.25b) * Rd(0.33%) * (1-Tc(0.21)))
Discount Rate = 6.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 2.32%
[DCF] Terminal Value 80.82% ; FCFF base≈243.9m ; Y1≈160.1m ; Y5≈73.0m
[DCF] Fair Price = 3.99 (EV 2.33b - Net Debt 1.57b = Equity 760.8m / Shares 190.9m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 83.75 | EPS CAGR: 144.8% | SUE: -2.75 | # QB: 0
Revenue Correlation: 98.07 | Revenue CAGR: 17.06% | SUE: 1.10 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.30 | Chg7d=+0.000 | Chg30d=-0.002 | Revisions Net=+3 | Analysts=3
EPS current Year (2026-12-31): EPS=1.14 | Chg7d=+0.000 | Chg30d=+0.017 | Revisions Net=+3 | Growth EPS=+1521.4% | Growth Revenue=+12.8%
EPS next Year (2027-12-31): EPS=1.88 | Chg7d=+0.000 | Chg30d=-0.275 | Revisions Net=-2 | Growth EPS=+65.6% | Growth Revenue=+12.4%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)